- It looks like Amgen (AMGN -1%) is in fact pushing for a price tag lower than the $130 a share it offered this month for Onyx Pharmaceuticals (ONXX -0.4%).
- The spat over access to trial data on Kyrpolis looks like it hasn't been resolved. Reports earlier this week suggested that the dispute over access to data on Kyprolis had been taken care of, with ONXX agreeing to provide the information. However, ONXX has apparently balked, saying the data pertains to sensitive patient data.
- Amgen hasn't put a new offer on the table yet and is considering its next move.
at Nasdaq.com (Nov 17, 2014)